US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Autism Impact ETF

27.09

-0.0928-0.34%

Post-market: 27.090.00000.00%16:10 EDT

Volume:24

Turnover:657

Market Cap:1.35M

PE:- -

High:27.09

Open:27.18

Low:27.09

Close:27.18

52wk High:29.12

52wk Low:24.54

Shares:50.00K

Float Shares:50.00K

Volume Ratio:0.17

T/O Rate:0.05%

Dividend:0.01

Dividend Rate:0.02%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart

Neurotech raises $4.5m to fund pivotal ASD Phase III trial

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

SCIENTECH Shares Surge Over 18% in Morning Session Following Saudi Market Approval for Key Heart Devices

Neurotech taps $3.15m R&D tax loan to fund Phase III ASD trials

Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy

MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

NASDAQ TRADE HALT HALT NEWS PENDING AT 10:43 AM

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/ASD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","market":"US","secType":"STK","nameCN":"Defiance Autism Impact ETF","latestPrice":27.0891,"timestamp":1789588800000,"preClose":27.1819,"halted":0,"volume":24,"hourTrading":{"tag":"盘后","latestPrice":27.0891,"preClose":27.0891,"latestTime":"16:10 EDT","volume":6,"amount":162.53459999999998,"timestamp":1789589403835,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0034140365463783046,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Post-Mkt","change":-0.0928,"latestTime":"09-16 16:38:07 EDT","open":27.1819,"high":27.0891,"low":27.0891,"amount":657,"amplitude":0,"askPrice":40.53,"askSize":200,"bidPrice":13.51,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":27.1819,"nav":27.29,"aum":1364500,"dividendRate":0.00022,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.0891,"preClose":27.0891,"latestTime":"16:10 EDT","volume":6,"amount":162.53459999999998,"timestamp":1789589403835,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.168067},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.168067,"shares":50000,"dividePrice":0.00597,"high":27.0891,"amplitude":0,"preClose":27.1819,"low":27.0891,"week52Low":24.54,"pbRate":"--","week52High":29.12,"institutionHeld":0,"latestPrice":27.0891,"eps":0,"divideRate":0.00022,"volume":24,"delay":0,"ttmEps":0,"open":27.1819,"prevYearClose":29.12,"prevWeekClose":27.0409,"prevMonthClose":27.6173,"prevQuarterClose":26.76,"fiveDayClose":27.1679,"twentyDayClose":27.9923,"sixtyDayClose":25.1308},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASD\",params:#limit:5,,,undefined,":[{"date":"2026-06-24","symbol":"ASD","amount":0.00597,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-24","defaultRemindTime":1782307800000,"name":"Defiance Autism Impact ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-24","currency":"USD","dateTimestamp":1782273600000,"payDate":"2026-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASD\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-24","recordDate":"2026-06-24","paymentDate":"2026-06-25","value":0.00597,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162663","title":"Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162663?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"trial of ML-007C-MA in adults with schizophrenia experiencing an acute. exacerbation of psychosis. The trial met its primary endpoint, with the. 210/3 mg twice-daily dose demonstrating a statistically significant and. clinically meaningful reduction in PANSS total score compared with. -- ML-007C-MA also demonstrated improvement on a prespecified. impairment and significant separation on key secondary endpoints,including CGI-S and the PANSS Marder positive factor.-- ML-007C-MA was generally well tolerated, with no serious or drug-related. severe adverse events and low rates of GI-related discontinuations. Its. clinical profile, including simple initiation, 99% of patients reaching","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2764262908.HKD","LU0868494617.USD","LU0174119429.USD","BK4613","STBQ","LATR","LU0353189763.USD","ASD","LU1316542783.SGD","LU1145028129.USD","LU0006306889.USD","LU2417539215.USD","ADP","FDFF","LU1236620750.USD","LU2361044865.SGD","IE000F7OJYX1.SGD","UYG","IE00B1XK9C88.USD","IE00BJJMRX11.SGD","LU0061474705.USD","LU2404859667.USD","LU1718418525.SGD","LU1084165304.USD","IE0005OL40V9.USD","LU2023250504.SGD","IE00BQXX3C00.GBP","LU2347655073.USD","LU0942090050.USD","IE00B775H168.HKD","LU1623119135.USD","LU0672654240.SGD","VFH","MA","MPLT","LU0965509010.AUD","LU2462157665.USD","LU0056508442.USD","IE000WAW04H5.SGD","LU2168564222.USD","LU1989764748.USD","XLF","LU0234570918.USD","FNCL","BK4559","LU2360107671.USD","IYG","IE00BYQQ9H92.USD","BK4585","IPAY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136535851","title":"Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136535851","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136535851?lang=en_us&edition=fundamental","pubTime":"2026-08-08 16:20","pubTimestamp":1786177220,"startTime":"0","endTime":"0","summary":"Qianli Intelligent Driving has announced that its ASD 4.0 assisted driving system has been production-ready and launched in the new smart #1, following its earlier integration in the smart #6. This...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656886125","title":"Neurotech raises $4.5m to fund pivotal ASD Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656886125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656886125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:38","pubTimestamp":1785800292,"startTime":"0","endTime":"0","summary":"An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has secured binding commitments for a $4.5 mil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","ASD","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704201","title":"Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176580,"startTime":"0","endTime":"0","summary":"-- Positive clinical data presented at EHA for iadademstat in first line. in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS. mutations; the triplet continued to demonstrate a favorable safety. gilteritinib continued to show a favorable safety profile and a high CRc. -- Enrollment initiated in Phase II trial of iadademstat in essential. -- U.S. patent granted for vafidemstat in borderline personality disorder. -- Cash position as of June 30, 2026 was $16.7 million ,excluding the gross proceeds of EUR12.0 million  raised in. -- On July 1, 2026, the company entered into a financing agreement with. COFIDES with a commitment to invest EUR25 million in future capital","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCD","BK4144","AMLP","BK4585","BK4588","BK4581","AMZA","BK4161","BK4561","MLPA","UMI","TNGY","BK4590","TPZ","BK4202","EMLP","MDST","ENFR","EIPI","USAI","ASD","EIPX","NCI","ORR","ET","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2092627202.USD","BID","FDFF","LU0107464264.USD","LU0708995401.HKD","BK4527","MA","IE00B4JS1V06.HKD","LU0056508442.USD","LU0823417653.USD","LU1732800096.USD","LU1868836914.USD","MPLT","UYG","LU2077746001.SGD","VFH","LU1280957306.USD","BK4139","LU2168564149.EUR","IE00BKDWB100.SGD","BK4533","LU0642271901.SGD","LU1815333072.USD","LU0823421333.USD","LU2506951958.HKD","STBQ","LU1712237335.SGD","XLF","FNCL","LU2420271590.USD","LU1861217088.USD","LU0823434583.USD","LU1316542783.SGD","IPAY","BK4585","SG9999003800.SGD","IE000WAW04H5.SGD","LATR","LU0210533765.USD","LU0557290698.USD","LU0096362180.USD","ASD","LU2092937148.SGD","LU0823421416.USD","IYG","LU1718418525.SGD","LU2360107671.USD","LU2168563687.JPY","LU1983260115.SGD","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167544310","title":"SCIENTECH Shares Surge Over 18% in Morning Session Following Saudi Market Approval for Key Heart Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1167544310","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167544310?lang=en_us&edition=fundamental","pubTime":"2026-07-17 12:05","pubTimestamp":1784261101,"startTime":"0","endTime":"0","summary":"Shares of SCIENTECH (02291) surged more than 18% in the morning session.As of the latest update, the stock was up 16.49% to HK$13.07, with a trading turnover of approximately HK$50.09 million.The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","IPOS","ASD","KCAI","BK4585","02291","BK4588","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651358324","title":"Neurotech taps $3.15m R&D tax loan to fund Phase III ASD trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2651358324","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651358324?lang=en_us&edition=fundamental","pubTime":"2026-07-15 10:27","pubTimestamp":1784082433,"startTime":"0","endTime":"0","summary":"Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International has secured a $3.15 million secured loan from Rockford RDF, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-taps-3-15m-rd-tax-loan-to-fund-phase-iii-asd-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-taps-3-15m-rd-tax-loan-to-fund-phase-iii-asd-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BK4134","ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651147194","title":"Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651147194","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651147194?lang=en_us&edition=fundamental","pubTime":"2026-07-14 07:21","pubTimestamp":1783984875,"startTime":"0","endTime":"0","summary":"Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has secured U.S. FDA clearance for its Investigational New Dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-clearance-for-nti164-bolstering-global-asd-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-clearance-for-nti164-bolstering-global-asd-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4585","BK4588","LABU","ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645489021","title":"MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645489021","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645489021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":"The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315170/0/en/MapLight-Announces-Topline-Results-from-Phase-2-IRIS-Study-for-ML-004-in-Autism-Spectrum-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABI","SPB","BK4018","ASD","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643478322","title":"Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2643478322","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643478322?lang=en_us&edition=fundamental","pubTime":"2026-06-15 02:45","pubTimestamp":1781462700,"startTime":"0","endTime":"0","summary":"Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311468/0/en/Crinetics-Presents-Long-Term-Data-at-ENDO-2026-Confirming-PALSONIFY-paltusotine-Provides-Durable-Consistent-Acromegaly-Control.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4585","BK4551","BK4588","ENDO","PTH","BK4535","BK4183","ASD","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640950765","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 10:43 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2640950765","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640950765?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:43","pubTimestamp":1780324981,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 10:43 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAQN2M1J9O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639619577","title":"Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639619577","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639619577?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:30","pubTimestamp":1780000200,"startTime":"0","endTime":"0","summary":"Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data dem","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303298/28908/en/Tonix-Pharmaceuticals-Presented-Retrospective-U-S-Real-World-Claims-Analysis-of-Opioid-Use-in-Patients-with-Fibromyalgia-at-the-2026-American-Society-of-Clinical-Psychopharmacology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNS","LU2360032135.SGD","LU2125154935.USD","BK4135","BK4161","AUC","BK4117","HI","LU0053687314.USD","LU2045819591.USD","BK4107","BK4174","BK4123","LU0029874061.USD","LU2125154778.USD","ASR","LU0210535034.USD","AFG","TNXP","ASD","BK4583","LU2125910500.SGD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}